MTSR Stock Recent News

MTSR LATEST HEADLINES

MTSR Stock News Image - zacks.com

The average of price targets set by Wall Street analysts indicates a potential upside of 89.7% in Metsera Inc. (MTSR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

zacks.com 2025 Jun 24
MTSR Stock News Image - globenewswire.com

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11 at 10:00 – 10:35 A.M. EDT. A live webcast and replay of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com.

globenewswire.com 2025 Jun 10
MTSR Stock News Image - benzinga.com

Metsera, Inc. MTSR on Monday released topline data from the Phase 1 clinical trial of MET-233i, an ultra-long-acting amylin analog engineered for class-leading durability, potency and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i.

benzinga.com 2025 Jun 09
MTSR Stock News Image - reuters.com

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a monthly dosing regime.

reuters.com 2025 Jun 09
MTSR Stock News Image - globenewswire.com

Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and  potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i.

globenewswire.com 2025 Jun 09
MTSR Stock News Image - globenewswire.com

Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations

globenewswire.com 2025 Jun 05
6 of 6